Brunke Karen J 4

What Happened

• Karen J. Brunke, a director of CytoDyn Inc. (CYDY), was granted an equity award reported as a derivative acquisition of 574,385 shares on March 20, 2026. The Form 4 lists the acquisition price as $0.00 and a reported value of $0 (derivative).

Key Details

• Transaction date: 2026-03-20; Form filed 2026-03-24.
• Reported terms: 574,385 shares @ $0.00 (derivative); listed as an award/grant (transaction code A).
• Footnote F1: Grant approved by the Compensation Committee on March 20, 2026, using shares reserved under the Issuer’s 2012 Equity Incentive Plan (as amended).
• Footnote F2: The stock option award vests in 12 approximately equal monthly installments, beginning April 2026 through March 2027.
• Shares owned after the transaction: not specified on the provided excerpt of the filing.
• Filing timeliness: no late-filing flag provided in the summary information.

Context

• This was a compensatory equity award (derivative), not an open-market purchase or sale. Such awards are common as director compensation and vest over time; they do not necessarily indicate immediate buying or selling by the insider. The Form 4 reports the grant price as $0.00, which reflects how the award is recorded on the filing, not the market value of the underlying shares.